Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M09D1 in Advanced Gastrointestinal and Other Solid Tumors
NCT06954077Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M09D1 in gastrointestinal tumor and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started May 2025; status: recruiting.
02
Drugs
BL-M09D1
03
Conditions
gastrointestinal tumorsolid tumor
Beyond the preview
Go deeper on NCT06954077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954077.